Abstract:ABSTRACT Increasing evidence supports the repositioning of beta-lactams for tuberculosis (TB) therapy, but further research on their interaction with conventional anti-TB agents is still warranted. Moreover, the complex cell envelope of Mycobacterium tuberculosis ( Mtb ) may pose an additional obstacle to beta-lactam diffusion. In this context, we aimed to identify synergies between beta-lactams and anti-TB drugs ethambutol (EMB) and isoniazid (INH) by assessing antimicrobial effects, intracellular activity, and immune responses. Checkerboard assays with H37Rv and eight clinical isolates, including four drug-resistant strains, exposed that only treatments containing EMB and beta-lactams achieved synergistic effects. Meanwhile, the standard EMB and INH association failed to produce any synergy. In Mtb -infected THP-1 macrophages, combinations of EMB with increasing meropenem (MEM) concentrations consistently displayed superior killing activities over the individual antibiotics. Flow cytometry with BODIPY FL vancomycin, which binds directly to the peptidoglycan (PG), confirmed an increased exposure of this layer after co-treatment. This was reinforced by the high IL-1β secretion levels found in infected macrophages after incubation with MEM concentrations above 5 mg/L, indicating an exposure of the host innate response sensors to pathogen-associated molecular patterns in the PG. Our findings show that the proposed impaired access of beta-lactams to periplasmic transpeptidases is counteracted by concomitant administration with EMB. The efficiency of this combination may be attributed to the synchronized inhibition of arabinogalactan and PG synthesis, two key cell wall components. Given that beta-lactams exhibit a time-dependent bactericidal activity, a more effective pathogen recognition and killing prompted by this association may be highly beneficial to optimize TB regimens containing carbapenems. IMPORTANCE Addressing drug-resistant tuberculosis with existing therapies is challenging and the treatment success rate is lower when compared to drug-susceptible infection. This study demonstrates that pairing beta-lactams with ethambutol (EMB) significantly improves their efficacy against Mycobacterium tuberculosis ( Mtb ). The presence of EMB enhances beta-lactam access through the cell wall, which may translate into a prolonged contact between the drug and its targets at a concentration that effectively kills the pathogen. Importantly, we showed that the effects of the EMB and meropenem (MEM)/clavulanate combination were maintained intracellularly. These results are of high significance considering that the time above the minimum inhibitory concentration is the main determinant of beta-lactam efficacy. Moreover, a correlation was established between incubation with higher MEM concentrations during macrophage infection and increased IL-1β secretion. This finding unveils a previously overlooked aspect of carbapenem repurposing against tuberculosis, as certain Mtb strains suppress the secretion of this key pro-inflammatory cytokine to evade host surveillance.

The Gene and Regulatory Network Involved in Ethambutol Resistance in Mycobacterium Tuberculosis.

Mycobacterial ethambutol responsive genes and implications in antibiotics resistance

Ethambutol targets the glutamate racemase of Mycobacterium tuberculosis-an enzyme involved in peptidoglycan biosynthesis

Mbtd and Cela1 Association with Ethambutol Resistance in Mycobacterium Tuberculosis: A Multiomics Analysis.

[The Mutations on embA, embB and embC Gene Region in Ethambutol-Resistant and Susceptible Clinical Mycobacterium tuberculosis Complex Isolates]

Mutations in the embC-embA intergenic region contribute to Mycobacterium tuberculosis resistance to ethambutol.

Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis

Ubia (rv3806c) Encoding DPPR Synthase Involved in Cell Wall Synthesis is Associated with Ethambutol Resistance in Mycobacterium Tuberculosis.

Mutations Found in Embcab, Embr, and Ubia Genes of Ethambutol-Sensitive and -Resistant Mycobacterium Tuberculosis Clinical Isolates from China

Concomitant Resistance to Ethambutol, Isoniazid and Rifampicin in Mycobacterium Tuberculosis Isolates from China

Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis

Genome-wide DNA Methylation and Transcriptome Changes in Mycobacterium Tuberculosis with Rifampicin and Isoniazid Resistance.

Omics analysis of Mycobacterium tuberculosis isolates uncovers Rv3094c, an ethionamide metabolism-associated gene

Structures of Cell Wall Arabinosyltransferases with the Anti-Tuberculosis Drug Ethambutol

Sequencing of EmbB Mutation in 10 Ethambutol- Resistant M. Tuberculosis Isolates

Study on the genes for drug resistance of cell-wall deficient M. tuberculosis

Identification of potential molecular targets and repurposed drugs for tuberculosis using network-based screening approach, molecular docking, and simulation

Study on embB Gene of the Stable L-form of Mycobcterium Tuberculosis

Discovery of dual-active ethionamide boosters inhibiting the Mycobacterium tuberculosis ESX-1 secretion system

Gene Expression Analysis of Two Extensively Drug-Resistant Tuberculosis Isolates Show That Two-Component Response Systems Enhance Drug Resistance

Characteristics of Embb Mutations in Multidrug-Resistant Mycobacterium Tuberculosis Isolates in Henan, China